Hemispherix starts Phase IIb Ampligen studies

HEB began two U.S. Phase IIb trials of its Ampligen nucleic acid 2-5A enzyme activator to treat or prevent infections with multi-drug resistant HIV in 250 patients with HIV/AIDS. ...